For immediate release |
|
THIS ANNOUNCEMENT, INCLUDING THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) 596 / 2014 WHICH FORMS PART OF
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Result of Retail Offer
The Board of Oncimmune Holdings plc (the "Company") announces that the Retail Offer launched on 18 October 2024 has now closed, and has raised
Application will be made to the London Stock Exchange for the admission of 946,736 Retail Offer Shares to trading on AIM on 11 November 2024 ("Second Admission") subject to Shareholders passing the proposed Resolutions at the General Meeting to be held at 11:00 a.m. on 8 November 2024. These new Ordinary Shares will rank pari passu with the Existing Ordinary Shares.
A separate announcement will be made following the General Meeting as to the results of the General Meeting and the total voting rights following Second Admission.
Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the announcement of the Fundraising made by the Company on 18 October 2024.
For further information:
Oncimmune Holdings plc
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist Sales)
Ondraya Swanson (ECM)
+44 (0) 20 7220 0500
Zeus (Joint Broker)
Dominic King, Dan Bate
+44 (0)20 3829 5000
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.